The relation between ERCC1 expression and resistance to platinum compounds had been found by some clinical studies in patients with advanced-stage gastric, ovarian, colorectal, esophageal, and non-small-cell lung cancers [15,17,19-21]. Here, ERCC1 is linked to non-small cell lung carcinoma.